Protocol for Alpha MSH Infusion Study in Patients With Type 2 Diabetes

Inclusion Criteria: * People with T2DM treated with oral or injectable medications which have been stable for 3 months, but not insulin therapy for type 2 diabetes. * Stable body weight and HbA1c for at least 3 months * The participant is capable of giving written informed consent * The participant is able to read, comprehend and record information written in English Exclusion Criteria: * Previous or current psychiatric diagnosis listed in DSM-V Axis 1. * Significant current or past medical or psychiatric history that, in the opinion of the investigators, contraindicates their participation. * History of type 1 diabetes mellitus. * History of endocrine disorder. * History of ischaemic heart disease, hypertension (current BP \> 160/95 mmHg), heart failure, cardiac arrhythmia, peripheral vascular or cerebrovascular disease. * History or presence of significant respiratory, gastrointestinal, hepatic, oncological, neurological or renal disease or other condition that in the opinion of the Investigators may affect participant safety or outcome measures. * Unwillingness or inability to follow the procedures outlined in the protocol. * History of sensitivity to any of the peptides, or components thereof, or a history of drug or other allergy that, in the opinion of the investigators, contraindicates their participation. * Use of current regular prescription or over-the-counter medications that in the opinion of the Investigators may affect participant safety or outcome measures. * Clinically significant abnormalities in screening electrocardiogram (ECG) or blood tests abnormalities which in the opinion of the study physician, is clinically significant and represents a safety risk. * Current pregnancy or breast-feeding in female participants (the investigators would advise using contraception for the duration of the study). * Pulse rate \<40 or \>100 beats per minute OR systolic blood pressure \>160 and \<100 and a diastolic blood pressure \>95 and \<50 in the semi-supine position. * The participant has participated in a clinical trial and has received an investigational product within the following time period prior to the first experimental visit in the current study: 90 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer). * Exposure to more than 3 new investigational medicinal products within 12 months prior to the screening. * Participants who have donated, or intend to donate, blood within three months before the screening visit or following study visit completion.